BioAge Labs, Inc. (BIOA) NASDAQ
18.49
+1.5(+8.83%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
18.49
+1.5(+8.83%)
Currency In USD
| Previous Close | 18.49 |
| Open | 17.38 |
| Day High | 18.9 |
| Day Low | 17.2 |
| 52-Week High | 24 |
| 52-Week Low | 3.67 |
| Volume | 3,328 |
| Average Volume | 603,900 |
| Market Cap | 665.27M |
| PE | -8.25 |
| EPS | -2.24 |
| Moving Average 50 Days | 19.21 |
| Moving Average 200 Days | 11.23 |
| Change | 18.49 |
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 9:30 PM GMT
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
GlobeNewswire Inc.
Jan 22, 2026 3:30 AM GMT
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o
BioAge Announces Proposed Public Offering
GlobeNewswire Inc.
Jan 20, 2026 9:01 PM GMT
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o